Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD

NCT06492863 is registered in ClinicalTrials.gov with Frontera Therapeutics as lead sponsor.

NCT NCT06492863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06492863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD
Lead sponsor
Frontera Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 15, 2023
Completion date
October 15, 2028
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration